切换至 "中华医学电子期刊资源库"
高级检索
中华临床实验室管理电子杂志

中华临床实验室管理电子杂志 ›› 2021, Vol. 09 ›› Issue (02) : 99 -104. doi: 10.3877/cma.j.issn.2095-5820.2021.02.008

所属专题： 文献；

大数据分析

多数据库分析HELQ基因在肾透明细胞癌中的表达及临床应用价值
何晓慧1, 罗芳2, 王海龙3, 刘昭廷2,†()   
  1. 1. 510515　广东广州，南方医科大学发育生物学教研室；201210　上海，上海科技大学生命科学与技术学院
    2. 510515　广东广州，南方医科大学发育生物学教研室
    3. 510182　广东广州，广州医科大学金域检验学院
  • 收稿日期:2020-12-17 出版日期:2021-05-28
  • 通信作者: 刘昭廷

Multi-database analysis of HELQ expression in renal clear cell carcinoma and its clinical application value

Xiaohui He1, Fang Luo2, Hailong Wang3, Zhaoting Liu2,†()   

  1. 1. Department of Developmental Biology, School of Basic Medical Sciences, Southern Medical University, Guangzhou Guangdong 510515, China; School of life science and technology, Shanghaitech University, Shanghai 201210, China
    2. Department of Developmental Biology, School of Basic Medical Sciences, Southern Medical University, Guangzhou Guangdong 510515, China
    3. Kingmed School of Laboratory Medicine, Guangzhou Medical University, Guangzhou Guangdong 510182, China
  • Received:2020-12-17 Published:2021-05-28
  • Corresponding author: Zhaoting Liu
全文 ( ) 下载PDF ( ) 导出引用
引用本文：

何晓慧, 罗芳, 王海龙, 刘昭廷. 多数据库分析HELQ基因在肾透明细胞癌中的表达及临床应用价值[J/OL]. 中华临床实验室管理电子杂志, 2021, 09(02): 99-104.

Xiaohui He, Fang Luo, Hailong Wang, Zhaoting Liu. Multi-database analysis of HELQ expression in renal clear cell carcinoma and its clinical application value[J/OL]. Chinese Journal of Clinical Laboratory Management(Electronic Edition), 2021, 09(02): 99-104.

目的

探索HELQ及同源重组通路相关基因在肾透明细胞癌中的表达情况及对患者生存的影响。

方法

采用GEPIA和UALCAN网站分析HELQ mRNA在肾透明细胞癌及正常肾组织中的表达情况；利用R2网站分析HELQ mRNA表达量与肾透明细胞癌分级的关系；通过LinkedOmics和R2网站分析HELQ mRNA表达量与肾透明细胞癌TNM分期之间的关系；选择UALCAN，Kaplan-Meier Plotter，OncoLnc网站分析HELQ mRNA表达水平对肾透明细胞癌患者的生存影响；并利用R2网站分析同源重组通路相关基因对肾透明细胞癌患者的生存影响。

结果

肾透明细胞癌中的HELQ mRNA表达量低于正常肾组织(P＜0.01)；HELQ mRNA表达量随着肾透明细胞癌分级(P＜0.01)、分期增加有降低的趋势。发生淋巴结转移和远处转移的肾透明细胞癌患者的HELQ mRNA表达水平低于未发生淋巴结转移和远处转移患者，差异具有统计学意义(P＜0.01)；HELQ mRNA表达量与肾透明细胞癌患者的预后呈正相关(P＜0.01)。同源重组通路有21个基因表达量对肾透明细胞癌患者的生存也存在影响。

结论

HELQ可能与肾透明细胞癌的发生发展有关系。

关键词: HELQ, 肾透明细胞癌, 预后, 网站分析
Objective

To investigate the expression of HELQ and homologous reconbination pathway related genes in renal clear cell carcinoma (ccRCC) and the effect on patients' survival.

Methods

Expression of HELQ mRNA in ccRCC and normal samples were determined by websites of GEPIA and UALCAN. R2 website was used to analyze the relationship between the expression of HELQ mRNA and the grade of renal clear cell carcinoma. The relationship between HELQ mRNA expression and TNM staging was investigated by LinkedOmics and R2. We also used UALCAN, Kaplan-Meier Plotter, OncoLnc to detect the expression of HELQ mRNA on ccRCC patients' survival. Finally, we explored the expression of genes in homologous recombination pathway on ccRCC patients' survival. R2 website was used to analyze the survival effect of homologous recombination pathway related genes on patients with renal clear cell carcinoma.

Results

Compared to normal renal tissues, expression of HELQ was lower in clear cell renal cell carcinoma (P＜0.01). Expression of HELQ tended to decrease with grades (P＜0.01) and the stages of renal clear cell cell carcinoma. Besides patients with lymphatic metastasis and distant metastasis had lower HELQ mRNA expression (P＜0.01). Expression of HELQ was positively correlated with patients' survival (P＜0.01). The expression of 21 genes in homologous recombination pathway also influenced ccRCC patients' survival.

Conclusion

HELQ may have relationship with the development of renal clear cell cell carcinoma.

Key words: HELQ, Clear cell renal cell carcinoma, Prognosis, Website analysis
图1 HELQ在ccRCC和正常肾组织HELQ mRNA的表达情况
图2 HELQ mRNA表达水平与ccRCC分级的关系。
图3 HELQ mRNA与ccRCC TNM分期之间的关系。3a，3b，3c为HELQ分析结果，来自LinkedOmics数据库。
图4 HELQ mRNA表达水平与ccRCC患者的生存期的关系。
表1 同源重组通路基因对ccRCC患者的生存影响
同源重组修复通路基因(来自KEGG)

P 值

(高表达vs低表达)

 短生存期患者表达水平(相对于正常人)
EME1 P＜0.01 高
RAD54L P＜0.01 高
XRCC3 P＜0.01 高
RAD51 P＜0.01 高
TOP3B P＜0.01 高
POLD1 P＜0.01 高
BLM P＜0.01 高
RAD52 P＜0.01 高
RAD51B P＜0.01 高
POLD4 P＜0.01 高
MUS81 P＜0.01 高
XRCC2 P＜0.01 高
RAD54B P＜0.01 高
SHFM1 P＜0.01 高
RAD51D P＜0.01 高
TOP3A P＜0.01 高
RPA4 P＜0.05 高
POLD3 P＜0.05 高
RPA1 P＜0.01 低
SYCP3 P＜0.01 低
RAD50 P＜0.01 低
1
Hsieh JJ, Purdue MP, Signoretti S, et al. Renal cell carcinoma[J]. Nat Rev Dis Primers, 2017, 317009.
2
Cancer Genome Atlas Research Network. Comprehensive molecular characterization of clear cell renal cell carcinoma[J]. Nature, 2013, 499(7456): 43-49.
3
Trivedi R, Dihazi GH, Eltoweissy M, et al. The antioxidant protein PARK7 plays an important role in cell resistance to Cisplatin-induced apoptosis in case of clear cell renal cell carcinoma[J]. Eur J Pharmacol, 2016, 78499-110.
4
Choueiri TK, Motzer RJ. Systemic Therapy for Metastatic Renal-Cell Carcinoma[J]. N Engl J Med, 2017, 376(4): 354-366.
5
Miao D, Margolis CA, Gao W, et al. Genomic correlates of response to immune checkpoint therapies in clear cell renal cell carcinoma[J]. Science, 2018, 359(6377):801-806.
6
Motzer RJ, Escudier B, McDermott DF, et al. Nivolumab versus Everolimus in Advanced Renal-Cell Carcinoma[J]. N Engl J Med, 2015, 373(19): 1803-1813.
7
Escudier B, Eisen T, Stadler WM, et al. Sorafenib in advanced clear-cell renal-cell carcinoma[J]. N Engl J Med, 2007, 356(2): 125-134.
8
Harmon CS, DePrimo SE, Figlin RA, et al. Circulating proteins as potential biomarkers of sunitinib and interferon-alpha efficacy in treatment-naive patients with metastatic renal cell carcinoma[J]. Cancer Chemother Pharmacol, 2014, 73(1): 151-161.
9
Motzer RJ, Escudier B, Oudard S, et al. Efficacy of everolimus in advanced renal cell carcinoma: a double-blind, randomised, placebo-controlled phase Ⅲ trial[J]. Lancet, 2008, 372(9637): 449-456.
10
Hudes G, Carducci M, Tomczak P, et al. Temsirolimus, interferon alfa, or both for advanced renal-cell carcinoma[J]. N Engl J Med, 2007, 356(22): 2271-2281.
11
Parikh M, JrLara PN. Modern Systemic Therapy for Metastatic Renal Cell Carcinoma of the Clear Cell Type[J]. Annu Rev Med, 2018, 69209-221.
12
Marini F, Kim N, Schuffert A, et al. POLN, a nuclear PolA family DNA polymerase homologous to the DNA cross-link sensitivity protein Mus308[J]. J Biol Chem, 2003, 278(34): 32014-32019.
13
Han X, Zhao L, Li X. HELQ in cancer and reproduction[J]. Neoplasma, 2016, 63(6): 825-835.
14
Adelman CA, Lolo RL, Birkbak NJ, et al. HELQ promotes RAD51 paralogue-dependent repair to avert germ cell loss and tumorigenesis[J]. Nature, 2013, 502(7471): 381-384.
15
Liu DN, Zhou YF, Peng AF, et al. HELQ reverses the malignant phenotype of osteosarcoma cells via CHK1-RAD51 signaling pathway[J]. Oncol Rep, 2017, 37(2): 1107-1113.
16
Tang Z, Li C, Kang B, et al. GEPIA: a web server for cancer and normal gene expression profiling and interactive analyses[J]. Nucleic Acids Res, 2017, 45(W1): W98-W102.
17
Chandrashekar DS, Bashel B, Balasubramanya SAH, et al. UALCAN: A Portal for Facilitating Tumor Subgroup Gene Expression and Survival Analyses[J]. Neoplasia, 2017, 19(8): 649-658.
18
Vasaikar SV, Straub P, Wang J, et al. LinkedOmics: analyzing multi-omics data within and across 32 cancer types[J]. Nucleic Acids Res, 2018, 46(1):956-963.
19
Menyhart O, Nagy A, Gyorffy B. Determining consistent prognostic biomarkers of overall survival and vascular invasion in hepatocellular carcinoma[J]. R Soc Open Sci, 2018, 5(12): 181006.
20
Dagher J, Delahunt B, Rioux-Leclercq N, et al. Clear cell renal cell carcinoma: validation of World Health Organization/International Society of Urological Pathology grading[J]. Histopathology, 2017, 71(6): 918-925.
21
Piazza A, Heyer WD. Homologous Recombination and the Formation of Complex Genomic Rearrangements[J]. Trends Cell Biol, 2019, 29(2): 135-149.
22
Mouw KW, Goldberg MS, Konstantinopoulos PA, et al. DNA Damage and Repair Biomarkers of Immunotherapy Response[J]. Cancer Discov, 2017, 7(7): 675-693.
23
O'Connor MJ. Targeting the DNA Damage Response in Cancer[J]. Mol Cell, 2015, 60(4): 547-560.
[1] 许杰, 李亚俊, 韩军伟. 两种入路下腹腔镜根治性全胃切除术治疗超重胃癌的效果比较[J/OL]. 中华普外科手术学杂志(电子版), 2025, 19(01): 19-22.
[2] 高杰红, 黎平平, 齐婧, 代引海. ETFA和CD34在乳腺癌中的表达及与临床病理参数和预后的关系研究[J/OL]. 中华普外科手术学杂志(电子版), 2025, 19(01): 64-67.
[3] 李代勤, 刘佩杰. 动态增强磁共振评估中晚期低位直肠癌同步放化疗后疗效及预后的价值[J/OL]. 中华普外科手术学杂志(电子版), 2025, 19(01): 100-103.
[4] 梁孟杰, 朱欢欢, 王行舟, 江航, 艾世超, 孙锋, 宋鹏, 王萌, 刘颂, 夏雪峰, 杜峻峰, 傅双, 陆晓峰, 沈晓菲, 管文贤. 联合免疫治疗的胃癌转化治疗患者预后及术后并发症分析[J/OL]. 中华普外科手术学杂志(电子版), 2024, 18(06): 619-623.
[5] 张志兆, 王睿, 郜苹苹, 王成方, 王成, 齐晓伟. DNMT3B与乳腺癌预后的关系及其生物学机制[J/OL]. 中华普外科手术学杂志(电子版), 2024, 18(06): 624-629.
[6] 屈翔宇, 张懿刚, 李浩令, 邱天, 谈燚. USP24及其共表达肿瘤代谢基因在肝细胞癌中的诊断和预后预测作用[J/OL]. 中华普外科手术学杂志(电子版), 2024, 18(06): 659-662.
[7] 顾雯, 凌守鑫, 唐海利, 甘雪梅. 两种不同手术入路在甲状腺乳头状癌患者开放性根治性术中的应用比较[J/OL]. 中华普外科手术学杂志(电子版), 2024, 18(06): 687-690.
[8] 付成旺, 杨大刚, 王榕, 李福堂. 营养与炎症指标在可切除胰腺癌中的研究进展[J/OL]. 中华普外科手术学杂志(电子版), 2024, 18(06): 704-708.
[9] 陈樽, 王平, 金华, 周美玲, 李青青, 黄永刚. 肌肉减少症预测结直肠癌术后切口疝发生的应用研究[J/OL]. 中华疝和腹壁外科杂志(电子版), 2024, 18(06): 639-644.
[10] 刘郁, 段绍斌, 丁志翔, 史志涛. miR-34a-5p 在结肠癌患者的表达及其与临床特征及预后的相关性研究[J/OL]. 中华消化病与影像杂志(电子版), 2024, 14(06): 485-490.
[11] 陈倩倩, 袁晨, 刘基, 尹婷婷. 多层螺旋CT 参数、癌胚抗原、错配修复基因及病理指标对结直肠癌预后的影响[J/OL]. 中华消化病与影像杂志(电子版), 2024, 14(06): 507-511.
[12] 曾明芬, 王艳. 急性胰腺炎合并脂肪肝患者CT 与彩色多普勒超声诊断参数与其病情和预后的关联性研究[J/OL]. 中华消化病与影像杂志(电子版), 2024, 14(06): 531-535.
[13] 沈炎, 张俊峰, 唐春芳. 预后营养指数结合血清降钙素原、胱抑素C及视黄醇结合蛋白对急性胰腺炎并发急性肾损伤的预测价值[J/OL]. 中华消化病与影像杂志(电子版), 2024, 14(06): 536-540.
[14] 王景明, 王磊, 许小多, 邢文强, 张兆岩, 黄伟敏. 腰椎椎旁肌的研究进展[J/OL]. 中华临床医师杂志(电子版), 2024, 18(09): 846-852.
[15] 郭曌蓉, 王歆光, 刘毅强, 何英剑, 王立泽, 杨飏, 汪星, 曹威, 谷重山, 范铁, 李金锋, 范照青. 不同亚型乳腺叶状肿瘤的临床病理特征及预后危险因素分析[J/OL]. 中华临床医师杂志(电子版), 2024, 18(06): 524-532.
阅读次数
全文


摘要

版权所有 中华医学会 中华医学电子音像出版社有限责任公司  京ICP备14006079号-1  网络出版服务许可证：(署)网出证(京)字第075号